Intas Pharmaceuticals has launched RAZUMAB, its biosimilar to Lucentis (ranibizumab).
Retina India is a not-for-profit organization, registered with the Charity Commissioner, Mumbai, India, established for empowering people with retinal disorders, and bringing them and their families on a common platform with physicians, researchers, counselors, low vision and mobility experts and other specialists.
Showing posts with label Diabetic macular edema. Show all posts
Showing posts with label Diabetic macular edema. Show all posts
Tuesday, June 23, 2015
Saturday, January 3, 2015
Poor Avastin responders in AMD & DME may have increased risk to obstructive sleep apnea
 |
| from Wikipedia |
Poor responders to Bevacizumab (Avastin) in patients with age-related macular degeneration (AMD) and diabetic macular edema (DME) may have increased risk to obstructive sleep apnea (OSA). To read more, click here.
Friday, September 19, 2014
EYLEA (aflibercept) injection receives FDA breakthrough therapy designation for diabetic retinopathy in patients with diabetic macular edema
Regeneron Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Eylea® (aflibercept) injection a breakthrough therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). The designation is based on positive results in two Phase 3 trials (VIVID-DME and VISTA-DME), in which Eylea demonstrated a statistically significant improvement
in a pre-specified measure of diabetic retinopathy in patients with DME after two years of treatment.
Subscribe to:
Posts (Atom)